Abstract
Cardiac myxomas are rare tumors that usually occur as sporadic lesions or, more rarely, in the familial form, mostly in the context of Carney complex (CNC). The molecular basis for the development of cardiac myxomas is unclear. However, somatic activating mutations in the GNAS1 gene (the gsp oncogene) are detected in the myocardium of McCune-Albright syndrome patients while germ-line mutations in the PRKAR1A gene are associated with CNC and familial myxomas. We investigated the presence of activating missense mutations in the GNAS1 gene as well as of inactivating mutations in PRKAR1A in 29 sporadically occurring cardiac myxomas. No gsp and no PRKAR1A mutations were found by direct sequencing of PCR products amplified from tumoral DNA. This is the first study including a large series of sporadic, isolated cardiac myxomas and showing that these cardiac neoplasms do not share the same mutations found in familial forms.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Amano J, Kono T, Wada Y, et al. Cardiac myxoma: its origin and tumor characteristics. Ann Thorac Cardiovasc Surg 2003, 9: 215–21.
Reynen K. Cardiac myxomas. N Engl J Med 1995, 333: 1610–7.
Carney JA, Hruska L, Beauchamp GD, Gordon H. Dominant inheritance of the complex of myxomas, spotty pigmentation and endocrine overactivity. Mayo Clin Proc 1986, 61: 165–72.
Casey M, Mah C, Merliss AD, et al. Identification of a novel genetic locus for familial cardiac myxomas and Carney complex. Circulation 1998, 98: 2560–6.
Casey M, Vaughan CJ, He J, et al. Mutations in the protein kinase A R1 alpha regulatory subunit cause familial cardiac myxomas and Carney complex. J Clin Invest 2000, 106: R31–8.
Kirschner LS, Carney JA, Pack SD, et al. Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex. Nat Genet 2000, 26: 89–92.
Weinstein LS, Shenker A, Gejman PV, Merino MJ, Friedman E, Spiegel AM. Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med 1991, 325: 1688–95.
Schwindinger WF, Francomano CA, Levine MA. Identification of a mutation in the gene encoding the alpha subunit of the stimulatory G-protein of adenylyl cyclase in McCune-Albright syndrome. Proc Natl Acad Sci USA 1992, 89: 5152–6.
Bristow MR. The adrenergic nervous system in heart failure. N Engl J Med 1984, 311: 850–1.
Bristow MR, Ginsburg R, Minobe W, et al. Decreased catecholamine sensitivity and beta adrenergic receptor density in failing human heart. N Engl J Med 1982, 307: 205–11.
Osadchii OE. Cardiac hypertrophy induced by sustained b-adrenoreceptor activation: pathophysiological aspects. Heart Fail Rev 2007, 12: 66–86.
Mantovani G, Romoli R, Weber G, et al. Mutational analysis of GNAS1 in patients with pseudohypoparathyroidism: identification of two novel mutations. J Clin Endocrinol Metab 2000, 85: 4243–8.
Mantovani G, Ballare E, Giammona E, Beck-Peccoz P, Spada A. The gsalpha gene: predominant maternal origin of transcription in human thyroid gland and gonads. J Clin Endocrinol Metab 2002, 87: 4736–40.
Persani L, Lania A, Alberti L, et al. Induction of specific phosphodiesterase isoforms by constitutive activation of the cAMP pathway in autonomous thyroid adenomas. J Clin Endocrinol Metab 2000, 85: 2872–8.
Persani L, Borgato S, Lania A, et al. Relevant cAMP-specific phosphodiesterase isoforms in human pituitary: effect of Gs(alpha) mutations. J Clin Endocrinol Metab 2001, 86: 3795–800.
Libé R, Mantovani G, Bondioni S, et al. Mutational analysis of PRKAR1A and Gs(alpha) in sporadic adrenocortical tumors. Exp Clin Endocrinol Diabetes 2005, 113: 248–51.
Landis CA, Masters SB, Spada A, Pace AM, Bourne HR, Vallar L. GTPase inhibiting mutations activate the a chain of Gs and stimulate adenylyl cyclase in human pituitary tumors. Nature 1989, 340: 692–6.
Lyons J, Landis CA, Harsh G, et al. Two G protein oncogenes in human endocrine tumors. Science 1990, 249: 655–9.
Fragoso MC, Latronico AC, Carvalho FM, et al. Activating mutation of the stimulatory G protein (gsp) as a putative cause of ovarian and testicular human stromal Leydig cell tumors. J Clin Endocrinol Metab 1998, 83: 2074–8.
Bertherat J, Groussin L, Sandrini F, et al. Molecular and functional analysis of PRKAR1A and its locus (17q22–24) in sporadic adrenocortical tumors: 17q losses, somatic mutations, and protein kinase A expression and activity. Canc Res 2003, 63: 5308–19.
DeMarco L, Stratakis CA, Boson WL, et al. Sporadic cardiac myxomas and tumors from patients with Carney complex are not associated with activating mutations of the Gs alpha gene. Hum Genet 1996, 98: 185–8.
Mabuchi T, Shimizu M, Ino H, et al. PRKAR1A gene mutation in patients with cardiac myxoma. Int J Card 2005, 102: 273–7.
Yamasaki H, Mizusawa N, Nagahiro S, et al. GH-secreting pituitary adenomas infrequently contain inactivating mutations of PRKAR1A and LOH of 17q23–24. Clin Endocrinol (Oxf) 2003, 58: 464–70.
Fogt F, Zimmerman RL, Hartmann CJ, Brown CA, Narula N. Genetic alterations of Carney complex are not present in sporadic cardiac myxomas. Int J Mol Med 2002, 9: 59–60.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mantovani, G., Bondioni, S., Corbetta, S. et al. Analysis of GNAS1 and PRKAR1A gene mutations in human cardiac myxomas not associated with multiple endocrine disorders. J Endocrinol Invest 32, 501–504 (2009). https://doi.org/10.1007/BF03346496
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03346496